RESUMEN
Clinically, Wangbi Capsule (WBC) is widely used in the treatment of Rheumatoid arthritis (RA) because of its remarkable therapeutic effect. To reveal the mechanism, a pharmacokinetic-pharmacodynamic (PK-PD) model was developed for the first time to assess the relationship between time-concentration (dose)-effect. Freund's Complete Adjuvant was used to induce the adjuvant-induced arthritis model. Multi-indices were used to evaluate the therapeutic effect and an S-Imax PK-PD model was established based on the concentrations of osthole, 5-O-methylvisamminoside, cimifugin, albiflorin, paeoniflorin and icariin and the levels of interleukin-1ß and prostaglandin E2 using a two-compartment PK model together with a PD model with an effect-site compartment. The results suggest that WBC can treat RA by regulating the levels of prostaglandin E2 and interleukin-1ß. For the PK-PD model, the parameters indicated that WBC had a large safety margin and all six bioactive ingredients of WBC have therapeutic effects on RA. Among them icariin, osthole and 5-O-methylvisamminoside may be the main effective substances. This study provided a scientific basis for further study of population pharmacokinetics / population pharmacodynamics (PPK/PPD), to develop a reasonable administration plan and improve individualized drug therapy.
Asunto(s)
Antiinflamatorios , Artritis Experimental , Medicamentos Herbarios Chinos , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/química , Antiinflamatorios/farmacocinética , Antiinflamatorios/farmacología , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/metabolismo , Benzopiranos/sangre , Benzopiranos/farmacocinética , Hidrocarburos Aromáticos con Puentes/sangre , Hidrocarburos Aromáticos con Puentes/farmacocinética , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/farmacocinética , Medicamentos Herbarios Chinos/farmacología , Flavonoides/sangre , Flavonoides/farmacocinética , Adyuvante de Freund/efectos adversos , Glucósidos/sangre , Glucósidos/farmacocinética , Articulaciones/efectos de los fármacos , Articulaciones/metabolismo , Masculino , Medicina Tradicional China , Monoterpenos/sangre , Monoterpenos/farmacocinética , Ratas , Ratas Sprague-DawleyRESUMEN
The methods for quantification of highly potent analgesic agent (2R,4aR,7R,8aR)-4,7-dimethyl-2-(thiophen-2-yl)octahydro-2H-chromen-4-ol in rat whole blood and plasma were developed and validated using dried matrix spots (DMS) or fabric phase sorptive extraction (FPSE) techniques in combination with LC-MS/MS. 2-Adamantylamine hydrochloride was used as an internal standard (IS). Chromatographic separation was carried out on a reversed-phase column (2.0×75â¯mm, 5⯵m) using water containing 0.1% formic acid and methanol containing 0.1% formic acid as mobile phases in gradient mode at a flow rate of 200⯵L/min. The mass spectrometric detection was performed using electrospray ionization (ESI) in positive ion mode. MRM transitions were m/z 284.5â¯ââ¯137.2/157.4 for the analgesic agent and m/z 152.3â¯ââ¯93.1/107.2 for IS. Calibration curves were linear within 20-5000â¯ng/mL in dried plasma spots (DPS) or dried blood spots (DBS) experiments. The linearity was obtained in the range of 20-5000â¯ng/mL and 50-5000â¯ng/mL for plasma-FPSE and blood-FPSE experiments, respectively. The intra- and inter-day accuracy and precision did not exceed acceptable limits. The mean extraction recovery (%) was 26 for DPS, 25 for DBS, 38 for plasma-FPSE, 31 for blood-FPSE.
Asunto(s)
Analgésicos/sangre , Cromatografía Liquida/métodos , Pruebas con Sangre Seca/métodos , Espectrometría de Masas en Tándem/métodos , Tiofenos/sangre , Animales , Benzopiranos/sangre , Límite de Detección , Modelos Lineales , Ratas , Reproducibilidad de los ResultadosRESUMEN
mHA11, a 2-amino-4-phenyl-4H-chromene-3-carboxylate analog, is a microtubule-targeting agent discovered by our group through the modification of the Bcl-2 inhibitor HA14-1. mHA11 exhibits cytotoxicities against tumor cells with nM IC50 values, whereas it has only a minimal effect on normal cells. We explored the plasma pharmacokinetics, tissue distribution, and excretion of mHA11 in rats using a liquid chromatography/tandem mass spectrometry (LC-MS/MS) method. Next, we identified the metabolites of mHA11 and assessed the influence of cytochrome P450 (CYP) isozymes on mHA11 metabolism. We also examined the in vitro stability in rat plasma and rat liver microsomes (RLMs), the blood-to plasma (B/P) ratio, and the inhibitory effect on CYP isozyme activities. After oral administration at 5, 15, and 45â¯mg/kg, mHA11 was absorbed and eliminated rapidly. There was a linear correlation between the area under the concentration-time curve (AUC0-∞) and the dose (R2â¯=â¯0.983). The bioavailability of mHA11 was 4.1% at the oral dose of 15â¯mg/kg mHA11 was extensively distributed in various tissues and exhibited a high penetration into the brain. No significant parent drug was detected in urine or bile, and only 0.74% was recovered in feces, whereas two demethylated metabolites, M1 and M2, were found in the urine and feces, and further studies showed that CYP2C19 primarily contributed to metabolites formation. mHA11 was stable in rat plasma but degraded significantly in RLMs; its B/P ratio was 1.05 in rat blood. In addition, mHA11 dose-dependently inhibited the activities of rat CYP isozymes, including CYP1A2, CYP2C6, CYP2C11, CYP2D2, CYP2E1 and CYP3A2. The present study is the first report on the disposition of mHA11 in rats and provides important data for further research and development of this inhibitor.
Asunto(s)
Benzopiranos/farmacocinética , Moduladores de Tubulina/farmacocinética , Administración Oral , Animales , Benzopiranos/sangre , Benzopiranos/química , Cromatografía Líquida de Alta Presión , Sistema Enzimático del Citocromo P-450/química , Sistema Enzimático del Citocromo P-450/genética , Sistema Enzimático del Citocromo P-450/metabolismo , Estabilidad de Medicamentos , Humanos , Masculino , Microsomas Hepáticos/metabolismo , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Espectrometría de Masas en Tándem , Distribución Tisular , Moduladores de Tubulina/sangre , Moduladores de Tubulina/químicaRESUMEN
Coumarins in Cham-dang-gwi, the dried root of Angelica gigas Nakai (AGN), possess pharmacological effects on anemia, pain, infection, and articular rheumatism. The AGN root containes decursin (D), decursinol angelate (DA), nodakenin, and decursinol (DOH), a major metabolite of D and DA. The aim of this study was to develop a simultaneous determination method for these four coumarins in human plasma using ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Chromatographic separation was performed on dual columns (Kinetex® C18 column and Capcell core C18 column) with mobile phase consisting of water and acetonitrile at a flow rate of 0.3 mL/min using gradient elution. Multiple reaction monitoring was operated in positive ion mode with precursors to product ion transition values of m/z 328.9â228.8, 328.9â228.9, 409.4â248.8, and 246.8â212.9 to measure D, DA, nodakenin, and DOH, respectively. Linear calibration curves were fitted over concentration range of 0.05â»50 ng/mL for these four components, with correlation coefficient greater than 0.995. Inter- and intra-day accuracies were between 90.60% and 108.24%. These precisions were within 11.19% for all components. The established method was then applied to a pharmacokinetic study for the four coumarins after usual dosing in Korean subjects.
Asunto(s)
Angelica/química , Benzopiranos/sangre , Butiratos/sangre , Cumarinas/sangre , Glucósidos/sangre , Extractos Vegetales/administración & dosificación , Adulto , Benzopiranos/química , Butiratos/química , Cromatografía Líquida de Alta Presión , Cumarinas/química , Glucósidos/química , Humanos , Masculino , Estructura Molecular , Extractos Vegetales/sangre , Extractos Vegetales/química , Extractos Vegetales/farmacocinética , Espectrometría de Masas en Tándem , Adulto JovenRESUMEN
A readily applicable method was developed to determine the concentration level of zaltoprofen, a non-steroidal antiinflammatory drug from the propionic acid family, in human plasma. This method is based on manual-shaking-assisted dispersive liquid-liquid microextraction coupled with liquid chromatography with ultraviolet detection. Factors affecting the extraction efficiency were screened and optimized by experimental design using fractional factorial and central composite designs, respectively. Optimal conditions were: 220 µL of C2 H4 Cl2 (extraction solvent), 5 mL of 3.75% w/v NaCl aqueous solution at pH 2.0, and manual shaking for 13 s (65 times). The resulting extraction method yielded a reasonable enrichment factor of 18.0 (±0.6, n = 3) and extraction recovery of 86.0% (±3.3%, n = 3). The established method was validated for selectivity, linearity, precision, accuracy, matrix effect, recovery, dilution integrity, and stability, and it met the acceptable criteria for all of the tested parameters. Specifically, the method was linear in the range of 0.16-50.0 mg/L, precise (< 8.8% RSD), accurate (-7.5-5.6% deviation), and showed negligible matrix effects (96.1-106.4%) with high absolute recovery (94.5-97.7%). Compared with previous methods involving labor-intensive liquid-liquid extraction or non-specific protein precipitation, our method allows the simple, rapid, and efficient determination of zaltoprofen using the most affordable analytical instrument, liquid chromatography with ultraviolet detection.
Asunto(s)
Benzopiranos/sangre , Propionatos/sangre , Cromatografía Liquida , Humanos , Microextracción en Fase LíquidaRESUMEN
In this report, we disclose the design and synthesis of a series of pentafluorosulfanyl (SF5) benzopyran derivatives as novel COX-2 inhibitors with improved pharmacokinetic and pharmacodynamic properties. The pentafluorosulfanyl compounds showed both potency and selectivity for COX-2 and demonstrated efficacy in several murine models of inflammation and pain. More interestingly, one of the compounds, R,S-3a, revealed exceptional efficacy in the adjuvant induced arthritis (AIA) model, achieving an ED50 as low as 0.094 mg/kg. In addition, the pharmacokinetics of compound R,S-3a in rat revealed a half-life in excess of 12 h and plasma drug concentrations well above its IC90 for up to 40 h. When R,S-3a was dosed just two times a week in the AIA model, efficacy was still maintained. Overall, drug R,S-3a and other analogues are suitable candidates that merit further investigation for the treatment of inflammation and pain as well as other diseases where COX-2 and PGE2 play a role in their etiology.
Asunto(s)
Antiinflamatorios/química , Antiinflamatorios/uso terapéutico , Artritis Experimental/tratamiento farmacológico , Benzopiranos/química , Benzopiranos/uso terapéutico , Inhibidores de la Ciclooxigenasa 2/química , Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Inflamación/tratamiento farmacológico , Animales , Antiinflamatorios/sangre , Antiinflamatorios/farmacología , Artritis Experimental/enzimología , Benzopiranos/sangre , Benzopiranos/farmacología , Inhibidores de la Ciclooxigenasa 2/sangre , Inhibidores de la Ciclooxigenasa 2/farmacología , Humanos , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/enzimología , Inflamación/enzimología , Masculino , Ratones , Modelos Moleculares , Ratas Endogámicas Lew , Ratas Sprague-DawleyRESUMEN
Nanocomposites (NCs) based on Soluplus (SP) were fabricated by an electrohydrodynamic (EHD) method for the oral delivery of Angelica gigas Nakai (AGN). Nano-sized particles were obtained after dispersing the resultant, produced by the EHD technique, in the aqueous environment. AGN/SP2 (AGN:SP=1:2, w/w) NC dispersion in aqueous media exhibited a 130nm mean diameter, narrow size distribution, and robust stability in the tested concentration range of the ethanol extract of AGN (AGN EtOH ext) and at pH 1.2 and 6.8. Amorphization of the components of AGN and their interactions with SP in the AGN/SP2 NC formulation were demonstrated by X-ray diffractometry (XRD) analysis. The released amounts of decursin (D) and decursinol angelate (DA), major components of AGN, from NCs were improved compared with those from the AGN EtOH ext group at both pH 1.2 and 6.8. As D and DA can be metabolized into decursinol (DOH) in the liver after oral administration, the DOH concentrations in plasma were quantitatively determined to evaluate the oral absorption of AGN. In a pharmacokinetic study in rats, higher oral absorption and the maximum concentration in plasma (Cmax) were presented in the AGN/SP2 NC group compared with the AGN EtOH ext and AGN NC groups. These findings indicate the successful application of developed SP-based NCs for the oral delivery of AGN.
Asunto(s)
Angelica/química , Benzopiranos/farmacocinética , Butiratos/farmacocinética , Nanocompuestos/química , Raíces de Plantas/química , Administración Oral , Animales , Benzopiranos/sangre , Benzopiranos/aislamiento & purificación , Butiratos/sangre , Butiratos/aislamiento & purificación , Técnicas Electroquímicas , Hidrodinámica , Concentración de Iones de Hidrógeno , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Nanocompuestos/ultraestructura , Extractos Vegetales/química , Ratas , Ratas Sprague-DawleyRESUMEN
Ormeloxifene (ORM) is a non-steroidal, selective estrogen receptor modulator used as a once a week oral contraceptive and is intended for long-term clinical use by females. Therefore, a simple, sensitive and rapid LC-MS/MS method was developed and validated for simultaneous quantification of ORM and its active metabolite (7-desmethyl ormeloxifene, 7-DMO) in rat plasma. Also, the method was partially validated in human plasma. Chromatographic separation was achieved on Discovery HS C-18 column (5µm, 50×4.6mm) with mobile phase [acetonitrile: aqueous ammonium acetate (0.01M) buffer (85: 15, %v/v)] at a flow rate of 0.8mL/min. The calibration curve was linear (r≥0.99) for a concentration range of 0.78-100ng/mL for both the analytes. The precision (%RSD; ORM, 1.3 to 13.4; 7-DMO, 3.1 to 15.0) and accuracy (%bias; ORM, -13.8 to 12.5; 7-DMO, -10.6 to 6.8) in both rat and human plasma were within the acceptable limits. The recovery for ORM and 7-DMO was always >79.1% and >72.9%, respectively. Both the analytes were found stable in rat plasma even after 30 days of storage at -80°C and on being subjected to three freeze-thaw cycles. The method has not only short run time (3.5min) but requires a low plasma sample volume (20µL) and is the first reported LC-MS/MS method for simultaneous quantification of the marketed drug known as centchroman (INN: ormeloxifene) and the metabolite 7-DMO in plasma. The method was applied to evaluate drug-drug interaction of ORM with the commonly prescribed antidepressant drug sertraline using serial sampling in rats.
Asunto(s)
Benzopiranos/sangre , Benzopiranos/farmacocinética , Cromatografía Liquida/métodos , Anticonceptivos Orales/sangre , Anticonceptivos Orales/farmacocinética , Espectrometría de Masas en Tándem/métodos , Administración Oral , Animales , Benzopiranos/administración & dosificación , Benzopiranos/farmacología , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/farmacología , Interacciones Farmacológicas , Femenino , Fertilización/efectos de los fármacos , Humanos , Modelos Lineales , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Sertralina/farmacocinéticaRESUMEN
A rapid, precise and accurate method for the simultaneous determination of 5 polycyclic musks (PCMs) in biological fluids was developed by solid supported liquid-liquid extraction (SLE) coupled with gas chromatography-tandem mass spectrometry (GC-MS/MS). All parameters influencing SLE-GC-MS performance, including electron energy of electron-impact ionization source, collision energy for tandem mass spectrometer when operated in selected-reaction monitoring (SRM) mode, type and volume of elution reagent, nitrogen evaporation time, pH and salinity of sample have been carefully optimized. Eight milliliter of n-hexane was finally chosen as elution reagent. Blood and urine sample could be loaded into SLE cartridge without adjusting pH and salinity. Deuterated tonalide (AHTN-d3) was chosen as internal standard. The correlation coefficient (r(2)) of the calibration curves of target compounds ranged from 0.9996 to 0.9998. The dynamic range spanned over two orders of magnitude. The limit of detection (LOD) of target compounds in blood and urine ranged from 0.008 to 0.105µgL(-1) and 0.005 to 0.075µgL(-1), respectively. The developed procedure was successfully applied to the analysis of PCMs in human blood and urine obtaining satisfying recoveries on low, medium and high levels. The method was compared with SLE-GC-MS and shown one to two orders of magnitude improvement in sensitivity.
Asunto(s)
Cromatografía de Gases y Espectrometría de Masas/métodos , Extracción Líquido-Líquido/métodos , Perfumes , Hidrocarburos Policíclicos Aromáticos , Adulto , Benzopiranos/sangre , Benzopiranos/química , Benzopiranos/orina , Femenino , Humanos , Concentración de Iones de Hidrógeno , Límite de Detección , Modelos Lineales , Perfumes/análisis , Perfumes/química , Hidrocarburos Policíclicos Aromáticos/sangre , Hidrocarburos Policíclicos Aromáticos/química , Hidrocarburos Policíclicos Aromáticos/orina , Reproducibilidad de los Resultados , Cloruro de Sodio , Espectrometría de Masas en Tándem , Adulto JovenRESUMEN
1. This study explores the impact of permeability and P-glycoprotein (P-gp) efflux, upon brain exposure to etamicastat, a new dopamine-ß-hydroxylase (DBH) inhibitor and consequently brain levels of catecholamines. 2. Brain exposure to etamicastat (10 mg/kg), following intravenous administration to mice, was residual and upon oral administration of the same dose no compound was detected, concurring with the absence of effects upon brain catecholamines. The intravenous co-administration of elacridar (1.0 mg/kg), a known P-gp/BCRP dual modulator, significantly increased brain etamicastat exposure, but the levels attained were very low when compared to those of nepicastat, a centrally active DBH inhibitor. 3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat. The secretory efflux ratio in MDCK-II cells overexpressing human P-gp showed an efflux ratio greater than 2, for both compounds, which was significantly decreased by elacridar. Despite its lower bioavailability and higher clearance, as compared to nepicastat, etamicastat showed preferential distribution to peripheral tissues and high plasma free fraction (15.5%), which may explain its effects upon peripheral DBH and catecholamine levels. 4. Though P-gp-mediated efflux may contribute to the limited brain penetration of etamicastat, the low permeability along with the pharmacokinetic properties of etamicastat may be perceived as the main contributors for its peripheral selectivity, which is advantageous for a cardiovascular drug candidate.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Benzopiranos/farmacología , Encéfalo/metabolismo , Permeabilidad de la Membrana Celular/efectos de los fármacos , Imidazoles/farmacología , Tionas/farmacología , Acridinas/administración & dosificación , Acridinas/farmacología , Animales , Atenolol/farmacología , Benzopiranos/sangre , Benzopiranos/química , Benzopiranos/farmacocinética , Transporte Biológico/efectos de los fármacos , Proteínas Sanguíneas/metabolismo , Células CACO-2 , Catecolaminas/metabolismo , Perros , Dopamina beta-Hidroxilasa/antagonistas & inhibidores , Dopamina beta-Hidroxilasa/metabolismo , Humanos , Imidazoles/sangre , Imidazoles/química , Imidazoles/farmacocinética , Hígado/efectos de los fármacos , Hígado/metabolismo , Células de Riñón Canino Madin Darby , Masculino , Ratones , Propranolol/farmacología , Unión Proteica/efectos de los fármacos , Tetrahidroisoquinolinas/administración & dosificación , Tetrahidroisoquinolinas/farmacología , Tionas/sangre , Tionas/química , Tionas/farmacocinética , Distribución Tisular/efectos de los fármacosRESUMEN
Sauchinone, a biologically active lignan found in Saururus chinensis (Saururaceae), exerts various biological activities against jaundice, inflammatory disease, hepatic steatosis, and oxidative injury. Despite its diverse applications, there exists some information about sauchinone's pharmacokinetics but its tissue distribution, metabolism, and tentative metabolites have not been reported yet. Thus we investigated the pharmacokinetics of sauchinone in mice using microsampling and HPLC-MS/MS methods. Sauchinone presented linear pharmacokinetics at intravenous doses 7.5-20 mg/kg and oral doses 20-500 mg/kg. However, the metabolism of sauchinone was saturated and this agent presented nonlinear pharmacokinetics at 50 mg/kg in the intravenous study. At sauchinone 20 mg/kg the F of sauchinone was 7.76% of the oral dose despite that 77.9% of sauchinone was absorbed. This might be due to extensive metabolism of sauchinone in S9 fractions of liver and small intestine. Tentative metabolites of sauchinone by oxidation, dioxidation, methylation, demethylation, dehydrogenation, or bis-glucuronide conjugation were detected in plasma and S9 fractions of liver, intestine, and kidney. The distribution of sauchinone was considerably high (tissue-to-plasma (T/P) ratios, >1) in liver, small intestine, kidney, lung, muscle, fat, or mesentery after intravenous and oral administration and in stomach and large intestine only after oral administration. The protein binding value of sauchinone was 53.0%. These pharmacokinetic data of sauchinone provide an important basis for preclinical applications and experimental methods can be adjusted to evaluate the pharmacokinetics of natural products in mice.
Asunto(s)
Benzopiranos/farmacocinética , Dioxoles/farmacocinética , Administración Intravenosa , Administración Oral , Animales , Área Bajo la Curva , Benzopiranos/administración & dosificación , Benzopiranos/sangre , Benzopiranos/farmacología , Cromatografía Líquida de Alta Presión , Dioxoles/administración & dosificación , Dioxoles/sangre , Dioxoles/farmacología , Masculino , Ratones Endogámicos ICR , Espectrometría de Masas en Tándem , Distribución TisularRESUMEN
Xiamenmycin A is an antifibrotic leading compound with a benzopyran skeleton that is isolated from mangrove-derived Streptomyces xiamenensis. As a promising small molecule for fibrotic diseases, less information is known about its metabolic characteristics in vivo. In this study, the time-course of xiamenmycin A in mouse plasma was investigated by relative quantification. After two types of administration of xiamenmycin A at a single dose of 10 mg/kg, the plasma concentrations were measured quantitatively by LC-MS/MS. The dynamic changes in the xiamenmycin A concentration showed rapid absorption and quick elimination in plasma post-administration. Four metabolites (M1-M4) were identified in blood by UPLC-QTOF-MS, and xiamenmycin B (M3) is the principal metabolite in vivo, as verified by comparison of the authentic standard sample. The structures of other metabolites were identified based on the characteristics of their MS and MS/MS data. The newly identified metabolites are useful for understanding the metabolism of xiamenmycin A in vivo, aiming at the development of an anti-fibrotic drug candidate for the therapeutic treatment of excessive fibrotic diseases.
Asunto(s)
Benzopiranos/sangre , Fibrinolíticos/sangre , Treonina/análogos & derivados , Animales , Biotransformación , Cromatografía Líquida de Alta Presión , Femenino , Espectrometría de Masas , Ratones , Ratones Endogámicos C57BL , Espectrometría de Masas en Tándem , Treonina/sangreRESUMEN
A selective and sensitive liquid chromatography-mass spectrometry (MS) method was developed and validated for the determination of karanjin in rat plasma. The target analyte, together with the internal standard (warfarin), was extracted from rat plasma by liquid-liquid extraction with ethyl acetate. Chromatographic separation was performed on a ZORBAX SB-C18 column using a mixture of acetonitrile and 0.1% aqueous formic acid as the mobile phase with linear gradient elution. MS detection was performed on a single quadrupole MS by selected ion monitoring mode via a positive electrospray ionization source. The assay exhibited a linear dynamic range of 2.50-3,000 ng/mL for karanjin. The intra- and inter-day precision was <10.8%, and the intra- and inter-day accuracy was <9.2%. The validated method has been applied to the preclinical pharmacokinetic studies of karanjin following oral administration of 5, 10 and 20 mg/kg karanjin to rats.
Asunto(s)
Benzopiranos/sangre , Benzopiranos/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masa por Ionización de Electrospray/métodos , Animales , Benzopiranos/química , Modelos Lineales , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: LY500307 is a highly selective estrogen receptor ß (ERß) agonist, which loses its selectivity at high dose and leads to undesirable suppression of total testosterone (TT) concentration. The objective of the present analysis was to define the LY500307 dose with minimal effect on TT METHODS: LY500307 and TT concentrations were obtained from a single ascending-dose study in a total of 30 healthy male subjects. LY500307 (in the range of 0.5 to 500 mg) or placebo was administered orally as a single dose on 2 occasions with a 3-week washout period. A population pharmacokinetics/pharmacodynamics (PK/PD) model that integrated Fourier series in an indirect response model was developed to describe the circadian rhythm of TT and the exposure-response relationship of LY500307 on TT. RESULTS: The maximum TT suppression (Emax ) was approximately 28.6%. The potency (EC50 ) of LY500307 on TT suppression was approximately 1.69 ng/mL with a 95%CI of 0.871 to 4.44 ng/mL. This model could provide inferences on LY500307 dose levels that would result in various magnitudes of TT suppression. CONCLUSIONS: Population PK/PD modeling is a highly sensitive tool to detect exposure-response relationships on top of the complicated and highly variable circadian rhythm of TT.
Asunto(s)
Benzopiranos/administración & dosificación , Benzopiranos/farmacocinética , Receptor beta de Estrógeno/agonistas , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Moduladores Selectivos de los Receptores de Estrógeno/farmacocinética , Testosterona/sangre , Administración Oral , Adulto , Benzopiranos/efectos adversos , Benzopiranos/sangre , Biomarcadores/sangre , Ritmo Circadiano , Estudios Cruzados , Esquema de Medicación , Receptor beta de Estrógeno/metabolismo , Análisis de Fourier , Voluntarios Sanos , Humanos , Londres , Masculino , Persona de Mediana Edad , Modelos Biológicos , Dinámicas no Lineales , Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos , Moduladores Selectivos de los Receptores de Estrógeno/sangre , Método Simple Ciego , Adulto JovenRESUMEN
Despite the importance of sympathetic nervous system in pathophysiological mechanisms of cardiac heart failure and essential hypertension, therapy specifically targeting the sympathetic nervous system is currently underutilized. Etamicastat is a novel dopamine-ß-hydroxylase (DBH) inhibitor that is oxidized into BIA 5-965 and deaminated followed by oxidation to BIA 5-998, which represents 13% of total etamicastat and quantified metabolites. However, the primary metabolic pathway of etamicastat in rats was found to be the N-acetylation (BIA 5-961), which represents 44% of total etamicastat and quantified metabolites. Trace amounts of BIA 5-961 de-sulfated and S-glucuronide were also detected. All the main metabolites of etamicastat inhibited DBH with IC50 values of 306 (228, 409), 629 (534, 741), 427 (350, 522) nM for BIA 5-965, BIA 5-998 and BIA 5-961, respectively. However, only etamicastat (IC50 of 107 (94; 121) nM) was able to reduce catecholamine levels in sympathetic nervous system innervated peripheral tissues, without effect upon brain catecholamines. Quantitative whole body autoradiography revealed a limited transfer of etamicastat related radioactivity to brain tissues and the mean recovery of radioactivity was ~90% of the administered radioactive dose, eliminated primarily via renal excretion over 5 days. The absolute oral bioavailability of etamicastat was 64% of the administered dose. In conclusion, etamicastat is a peripheral selective DBH inhibitor mainly N-acetylated in the aminoethyl moiety and excreted in urine. Etamicastat main metabolites inhibit DBH, but only etamicastat demonstrated unequivocal pharmacological effects as a DBH inhibitor with impact upon the activity of the sympathetic nervous system under in vivo conditions.
Asunto(s)
Benzopiranos/farmacología , Dopamina beta-Hidroxilasa/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Imidazoles/farmacología , Acetilación , Glándulas Suprarrenales/efectos de los fármacos , Glándulas Suprarrenales/enzimología , Animales , Benzopiranos/sangre , Benzopiranos/farmacocinética , Benzopiranos/orina , Línea Celular Tumoral , Dopamina/metabolismo , Dopamina beta-Hidroxilasa/metabolismo , Inhibidores Enzimáticos/sangre , Inhibidores Enzimáticos/farmacocinética , Inhibidores Enzimáticos/orina , Heces/química , Glucuronosiltransferasa/metabolismo , Humanos , Imidazoles/sangre , Imidazoles/farmacocinética , Imidazoles/orina , Masculino , Ratones , Miocardio/metabolismo , Norepinefrina/metabolismo , Ratas Wistar , Proteínas Recombinantes/metabolismoRESUMEN
UNLABELLED: The aim of the study was to analyze the physicochemical synthesized complex 3 [(1,3- thiazol -2- ylimino) methyl)]-4H- chromene -4 -one with tetrachloroplatinate(II) dipotassium and determination peroxidase activity and glutathione (GPX) in red blood cells of cancer patients and healthy subjects. MATERIALS AND METHODS: Tests were carried out with the approval of the Bioethics Committee No. RNN/260/08/KB. Blood was collected into tubes with anticoagulant (heparin lithium). Determination of glutathione peroxidase activity was performed by methods of Little and O'Brien in 20 person groups hospitalized at the Department of General and Colorectal Surgery Veterans General Hospital in Lódz. RESULTS: The study was an increase of activity in the control without the compound and after the introduction of the complex relative to the treatment groups. In healthy subjects, without the use of glutathione peroxidase complex averaged 73.25 ± 23.88 U / g Hb after application of the compound corresponds to the reference group 81.01 ± 25.94 U / g Hb. In contrast, in patients without the use of the complex activity amounted to 42.85 ± 27.49 U / g Hb. In the study group, which uses synthesized complex GPX activity corresponds to 67.72 ± 13.44 U / g Hb. CONCLUSIONS: The obtained results underline that the introduction of significant blood antioxidant complex research has a significant impact on the results of the determinations. Statistically significant (p < 0.05) difference occurred in both test and no relation to the administration of the complex in relation to the control of 1. 2.
Asunto(s)
Benzopiranos/farmacología , Catalasa/sangre , Glutatión Peroxidasa/sangre , Glutatión/sangre , Neoplasias/enzimología , Platino (Metal)/farmacología , Superóxido Dismutasa/sangre , Adulto , Anciano , Antioxidantes/farmacología , Benzopiranos/sangre , Femenino , Voluntarios Sanos , Humanos , Peroxidación de Lípido/efectos de los fármacos , Masculino , Persona de Mediana Edad , Platino (Metal)/sangre , Polonia , Especies Reactivas de Oxígeno/sangreRESUMEN
A rapid, simple and sensitive, liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous determination of bergenin, chlorogenic acid and four flavonoids in a QingGanSanJie preparation in rat plasma. Puerarin was selected as the internal standard (IS). Plasma samples were precipitated with methanol and separated with a reverse phase Agilent Poroshell 120 EC-C18 column using a gradient mobile phase of methanol-water containing 0.1% formic acid (v/v). A triple quadruple mass spectrometer was used for quantification (limit of detection 0.36-5.55 ng/mL). Intra-day and inter-day precisions were within 15% and the average extraction recoveries ranged from 85 to 115% for each analyte. The method allowed simultaneous quantification for the first time of the pharmacokinetics of bergenin, chlorogenic acid and four flavonoids after intragastric administration of a QingGanSanJie extract in Sprague-Dawley rats. It was found that bergenin and chlorogenic acid had typical extravascular administration concentration-time curves; flavonoids had a bimodal distribution improving bioavailability and extending the pharmacodynamics period.
Asunto(s)
Benzopiranos/sangre , Ácido Clorogénico/sangre , Cromatografía Liquida/métodos , Medicamentos Herbarios Chinos/administración & dosificación , Flavonoides/sangre , Administración Oral , Animales , Benzopiranos/química , Benzopiranos/farmacocinética , Ácido Clorogénico/química , Ácido Clorogénico/farmacocinética , Estabilidad de Medicamentos , Medicamentos Herbarios Chinos/farmacocinética , Flavonoides/química , Flavonoides/farmacocinética , Límite de Detección , Modelos Lineales , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Espectrometría de Masas en Tándem/métodosRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Caesalpinia sappan is a medicinal plant native to China popularly used to treat chronic pelvic inflammation, dysmenorrhea and hysteromyoma. Its main bioactive component is brazilin which had presented antibacterial, anti-inflammatory and anti-platelet aggregation activities. To establish a sensitive, selective, reproducible, and accurate high performance liquid chromatographic (HPLC) method for the quantitative determination of brazilin in plasma, and study the pharmacokinetics of brazilin in rats after intravenous administration of brazilin. MATERIALS AND METHODS: Rats received intravenous injection of 25, 50 and 100mg/kg of brazilin. Concentrations of brazilin in plasma were determined by HPLC method at different time points and all pharmacokinetic parameters were estimated by non-compartmental analysis with WinNonLin 6.2 software. RESULTS: After single intravenous doses of 25, 50 and 100mg/kg brazilin in rats, the main PK parameters were as follows: Cmax were 18.1 ± 4.1, 46.7 ± 8.7 and 82.2 ± 9.6 µg/mL; AUC0-24 were 20.4 ± 4.3, 48.7 ± 6.8 and 90.4 ± 10.3 µgh/mL; and t1/2 were 5.4 ± 1.5, 5.8 ± 0.9 and 6.2 ± 1.2h, respectively. CONCLUSION: It showed that the brazilin was eliminated moderately in rat by intravenous injection route with t1/2 of 6h and showed a dose-dependence profile of Cmax and AUC0-24 at the doses of 25~100mg/kg of brazilin for injection in rats.
Asunto(s)
Benzopiranos/química , Benzopiranos/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Animales , Área Bajo la Curva , Benzopiranos/sangre , Relación Dosis-Respuesta a Droga , Semivida , Masculino , Estructura Molecular , Ratas , Ratas Sprague-Dawley , Sensibilidad y Especificidad , Tinidazol/química , Tinidazol/farmacocinéticaRESUMEN
Nebivolol is available for clinical use as a racemic mixture. Isomer d-nebivolol (SRRR) is a ß1 adrenergic receptor blocker and its antipode, l-nebivolol (RSSS) is responsible for endothelium-dependent NO liberation. This report describes the development and validation of a method of analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Nebivolol isomers were extracted from 2mL aliquots of plasma spiked with tramadol as internal standard, alkalinized and added of sodium chloride and diisopropyl ether:dichloromethane (70:30, v/v). Nebivolol isomers were resolved on a Chirobiotic(®) V column using methanol:acetic acid:diethylamine (100:0.15:0.05, v/v/v) as mobile phase. Protonated ion and respective ion product were monitored in transitions 406>151 for nebivolol and 264>58 for internal standard tramadol. There was no racemization of nebivolol isomers during the procedures of sample preparation and chromatographic analysis and matrix effect was absent. Analysis of nebivolol isomers showed linearity for plasma concentrations of 25-2500pg/mL of each isomer. The quantification limit was 25pg of each isomer/mL of plasma. Variation coefficients and inaccuracy calculated in precision and accuracy determinations were lower than 15%. Nebivolol was stable in human plasma after three successive cycles of freezing and thawing, during 4h at room temperature and after processing during 12h in the auto sampler at 5°C showing deviation values lower than 15%. The method was applied in a study of the kinetic disposition of nebivolol in plasma samples collected until 48h after administration of an oral single dose of 10mg of racemic nebivolol hydrochloride to a patient with systemic arterial hypertension. The clinical study demonstrated that the nebivolol pharmacokinetics is stereoselective. Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.
Asunto(s)
Benzopiranos/sangre , Cromatografía Líquida de Alta Presión/métodos , Etanolaminas/sangre , Espectrometría de Masas en Tándem/métodos , Adulto , Benzopiranos/química , Benzopiranos/aislamiento & purificación , Etanolaminas/química , Etanolaminas/aislamiento & purificación , Humanos , Isomerismo , Modelos Lineales , Nebivolol , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Personal care products (PCPs), such as soaps, perfumes, cosmetics, lotions, etc., contain a variety of chemicals that have been described as potentially hormone disrupting chemicals. Therefore, it is important to assess the internal exposure of these chemicals in humans. Within the 2nd Flemish Environment and Health Study (FLEHS II, 2007-2011), the human exposure to three classes of pollutants that are present in a wide variety of PCPs--i.e. polycyclic musks (galaxolide, HHCB and tonalide, AHTN in blood), parabens (urinary para-hydroxybenzoic acid, HBA) and triclosan (urinary TCS)--was assessed in 210 Flemish adolescents (14-15 years) and in 204 adults (20-40 years) randomly selected from the general population according to a stratified two stage clustered study design. The aim of this study was to define average levels of exposure in the general Flemish population and to identify determinants of exposure. Average levels (GM (95% CI)) in the Flemish adolescents were 0.717 (0.682-0.753) µg/L for blood HHCB; 0.118 (0.108-0.128) µg/L for blood AHTN; 1022 (723-1436) µg/L for urinary HBA and 2.19 (1.64-2.92) µg/L for urinary TCS. In the adults, levels of HBA were on average 634 (471-970) µg/L. Inter-individual variability was small for HHCB and AHTN, intermediate for HBA, and large for TCS. All biomarkers were positively associated with the use of PCPs. Additionally, levels of HHCB and AHTN increased with higher educational level of the adolescents. Both in adults and adolescents, urinary HBA levels were negatively correlated with BMI. We define here Flemish exposure values for biomarkers of PCPs, which can serve as baseline exposure levels to identify exposure trends in future biomonitoring campaigns.